Resverlogix Receives Two Patents for RVX-208 in China

CALGARY, Alberta, April 7, 2015 /PRNewswire/ — Resverlogix Corp. (“Resverlogix” or the “Company”) (TSX: RVX) announces that it has received two China patent approvals covering RVX-208. A composition of matter patent, China No. 2007 8 0052349.8 titled, “Compounds for the Prevention and Treatment of Cardiovascular Disease” was granted until February 2027. A manufacturing patent, China No. ZL 2009 8 0106586.7 titled, “Methods of Preparing Quinazolinone Derivatives” was granted until June 2029.

“These two additional patents build upon the growing intellectual property estate for our core asset, RVX-208. With our Chinese patent life extending out to June 2029, RVX-208 now has the necessary protection required for a regional licensing deal in China,” stated Donald McCaffrey, president and CEO of Resverlogix. Mr. McCaffrey added, “Resverlogix views the ever expanding Chinese pharmaceutical market as an attractive opportunity which aligns with our regional licensing strategy. We will continue our discussions with potential partners at the China Bio Partnering Forum in Shanghai next week.” On April 15th, Resverlogix is one of four selected Canadian companies who will be presenting at China Bio.

About RVX-208

RVX-208 is a first-in-class, small molecule selective BET bromodomain inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can turn disease-causing genes off, returning them to a healthier state. RVX-208 is the first and only BET inhibitor selective for BRD4-BD2, producing a nexus of biological effects with potentially important benefits for patients with diseases such as cardiovascular disease (CVD), diabetes mellitus (DM), Alzheimer’s disease, peripheral artery disease, and chronic kidney disease while maintaining an excellent safety profile. Resverlogix is planning to study RVX-208 in a proposed Phase 3 clinical trial in CVD patients with DM and low HDL.

About Resverlogix

Resverlogix Corp. is developing RVX-208, a first-in-class, small molecule selective BET bromodomain inhibitor for the potential treatment of patients with cardiovascular disease, diabetes mellitus, Alzheimer’s disease, peripheral artery disease, and chronic kidney disease. RVX-208 is the only selective BET bromodomain inhibitor in clinical trials. Resverlogix’s common shares trade on the Toronto Stock Exchange (TSX: RVX). For further information please visit www.resverlogix.com. We can be followed on our blog at http://www.resverlogix.com/blog and via Twitter https://twitter.com/resverlogix_rvx @Resverlogix_RVX.

This news release may contain certain forward-looking information as defined under applicable Canadian securities legislation, that are not based on historical fact, including without limitation statements containing the words “believes”, “anticipates”, “plans”, “intends”, “will”, “should”, “expects”, “continue”, “estimate”, “forecasts” and other similar expressions. In particular, this news release includes forward looking information relating to research and development activities and the potential role of RVX-208 in the treatment of cardiovascular disease, Alzheimer’s disease, peripheral artery disease and chronic kidney disease. Our actual results, events or developments could be materially different from those expressed or implied by these forward-looking statements. We can give no assurance that any of the events or expectations will occur or be realized. By their nature, forward-looking statements are subject to numerous assumptions and risk factors including those discussed in our Annual Information Form and most recent MD&A which are incorporated herein by reference and are available through SEDAR at www.sedar.com. The forward-looking statements contained in this news release are expressly qualified by this cautionary statement and are made as of the date hereof. The Company disclaims any intention and has no obligation or responsibility, except as required by law, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

For further information, please contact:

Company Contacts:
Donald J. McCaffrey
President and CEO
Resverlogix Corp.
Phone: +1-403-254-9252
Email: don@resverlogix.com

Sarah Zapotichny
Director, Investor Relations & Corporate Communications
Resverlogix Corp.
Phone: +1-403-254-9252
Email: sarah@resverlogix.com

Media:
Tony Russo, Ph.D.
Matt Middleman, M.D.
Russo Partners, LLC
Phone: +1-212 845 4251
Phone: +1-212-845-4272
Email: tony.russo@russopartnersllc.com
Email: matt.middleman@russopartnersllc.com

Novogen Engages Leading US Investor Relations Firm

SYDNEY, April 2, 2015 /PRNewswire/ — Novogen Ltd (ASX:NRT NASDAQ:NVGN) today announced it has appointed US-based public relations firm, PCG Advisory (PCG), to drive the Company’s investor-awareness program in the US. PCG will be using their expertise in creating awareness and establishing key relationships within the US investment community via their targeted outreach campaign.

Dr Graham Kelly said: “The investment community has reacted positively in recent times to the Company’s extensive drug discovery program and with significant growth in activity ahead in the short-term, we felt it was timely to appoint an advisory firm to build on that momentum and communicate our activities to the market to maximise shareholder value.  Showcasing the Company to the wholesale investment community is a key part of our strategy to bring new investors into the stock through on-market buying. We look forward to working with the PCG team.”

Jeff Ramson, Founder and CEO of PCG stated, “We are excited to work with the entire team at Novogen.  We have extensive experience with Australian emerging growth companies that have stakeholders on several continents.  We look forward to communicating the Novogen story to a larger group of US investors, who need to learn about their drug technology platforms and how management will execute the Company’s strategy in the short and long term. We look forward to the partnership.”

ABOUT PCG ADVISORY GROUP

Founded in 2008, PCG Advisory Group is dedicated to the delivery of top tier capital markets advisory services, strategic investor relations, tactical digital and social media communications and cutting edge media and public relations for public and privately held companies. The team at PCG has extensive experience with life sciences and healthcare, high technology, metals and mining, financial services and emerging growth companies from around the globe.

PCG’s Capital Markets Advisory Services include overall investor relations’ strategy development to increase and leverage investor awareness, visibility and credibility. PCG’s Social and Digital Media services include leveraging social and professional digital media sites to effectively and accurately communicate client stories. As an aggregation, distribution, and engagement platform, PCG reaches thousands of individual, retail, institutional investors, bankers and analysts using proprietary techniques, search engine optimization, online marketing, website development and our proprietary and extensive distribution network. PCG’s Media and Public Relations services are a strategic and integral component of all Corporate Communications. The media and public relations team works with print, broadcast, online news sites and bloggers to communicate the best client story at the right time. PCG also actively assists clients during the pre- and post-IPO process as well as through mergers, acquisitions, uplistings, and or a potential crisis. Communicating the client’s story accurately and effectively is tantamount to maximizing exposure to its current and potential stakeholders.

About Novogen Limited

Novogen is a public, drug-development company whose shares trade on both the Australian Securities Exchange (‘NRT’) and NASDAQ (‘NVGN’).  The Novogen Group includes a New Haven CT-based joint venture company, CanTx Inc., with Yale University.

Novogen has two main drug technology platforms: super-benzopyrans (SBPs) and anti-tropomyosins (ATMs).  SBP compounds have been created to kill the full range of cells within a tumor, but particularly the cancer stem cells.  The ATM compounds target the microfilament component of the cancer cell and when used in conjunction with standard anti-microtubule drugs, result in comprehensive and fatal destruction of the cancer cell’s cytoskeleton.  Ovarian cancer, colorectal cancer, malignant ascites, prostate cancer, neural cancers (glioblastoma, neuroblastoma in children) and melanoma are the key clinical indications being pursued, with the ultimate objective of employing both technologies as a unified approach to first-line therapy.

Further information is available on our websites www.novogen.com

For more information please contact:

Corporate Contact

Dr. Graham Kelly

Executive Chairman & CEO

Novogen Group

Graham.Kelly@novogen.com           

+61 (0) 2 9472 4100

Media Enquiries

Cristyn Humphreys

Chief Operating Officer

Novogen Group

Cristyn.Humphreys@novogen.com

+61 (0) 2 9472 4111

Nutrastar International, Inc. Announces Full Year 2014 Results

HARBIN, China, March 30, 2015 /PRNewswire/ — Nutrastar International Inc. (OTCQB: NUIN) (“Nutrastar” or the “Company”), a leading producer and supplier of premium branded consumer products, including commercially cultivated Cordyceps Militaris (“Cordyceps”), functional health beverages and organic and specialty foods, today announced its results for the full year ended December 31, 2014.

Financial Highlights for the Full Year Ended December 31, 2014

  • Net revenue was $43.33 million, as compared to $43.35 million in full year 2013.
  • Gross profit was $34.01 million, representing a gross margin of 78.5%.
  • Net income was $22.72 million, representing a net margin of 52.4%.
  • Basic and diluted EPS were $1.34 and $1.28, respectively, with 16.83 million basic shares and 17.70 million diluted shares outstanding.

Management Commentary

Ms. Lianyun Han, CEO of Nutrastar, commented, “Over the past few years, we have worked hard at expanding product offerings, increasing revenue and creating opportunities through product development and capacity expansion. Although revenue for 2014 came in slightly under our estimates, it was a successful year nonetheless marked by the expansion and realignment of our product offerings in order to better position ourselves to meet current and future market demand. For the full year 2014, we operated at full production capacity and with the benefit of these economies of scale, our gross margins improved to 78.5%, up from 77.8% in the prior year. We also experienced a sales increase of approximately 10% or $3.36 million in our core premium consumer product Cordyceps, which includes sales of our new soluble, on-the-go Cordyceps powder solution. As expected, due to the strategic product realignment implemented in early 2014, sales growth of our core Cordyceps product segment was partially offset by $3.47 million decrease in sales of our beverages product line, resulting in year-over-year flat revenue growth.”

Ms. Han continued, “Currently, we expect to continue operating at full production capacity and thus anticipate minimum year-over-year revenue growth in the current year. Since demand for our premium Cordyceps Militaris consumer products remains robust in our current markets, we will begin to evaluate avenues for future capacity expansion this year.

One of our 2015 priorities will be exploring opportunities and securing the export of our products to markets abroad. Since receiving initial export approval from China’s Ministry of Commerce as Foreign Trade Operator, we have been conducting and prototyping new product formats for select international markets such as South Korea and Hong Kong. We plan to evaluate and test our on-the-go soluble Cordyceps powder solution to determine its potential receptivity and viability in the U.S. market, and explore strategic packaging and distribution partners that will be integral to our international exportation approval and expansion efforts. It is our current intention to complete market testing, secure packaging and international distribution partners in 2015 and begin generating international sales revenue in 2016. We believe the international path is a vital part of the Company’s future growth plan and we are committed to ensuring it happens as soon as possible beginning with our powder solution. We will keep the public apprised as initiatives progress.

In closing, we believe 2015, despite our flat revenue growth expectations, will be a significant year that sets the stage for increased and sustained growth for the Company going forward. On behalf of the entire Nutrastar team, we would like to thank our shareholders and supporters for their continued patience and support for our Company and belief in our unique value proposition within the growing consumer product market. We look forward to sharing in our successes moving forward.”

Outlook for the Year Ending December 31, 2015

Based on management’s current expectations, full year 2015 revenue should be in the range of $43 million to $45 million.

Request for Call with Management

Investors are invited to request a call with Nutrastar’s management team. For those investors who are interested in speaking with management, please contact American Capital Ventures at +1-305-918-7000 to schedule.

For more information regarding Nutrastar’s financial performance during the full year ended December 31, 2014, please refer to the Annual Report on Form 10-K to be filed with the Securities and Exchange Commission on or about March 30, 2015.

About Nutrastar International Inc.

Nutrastar is a China based leading producer and supplier of premium branded consumer products including commercially cultivated Cordyceps Militaris, functional health beverages as well as specialty and organic foods. Cordyceps Militaris is one of the most highly regarded herbal nutrients in Traditional Chinese Medicine. The Company is headquartered in Harbin, capital of Heilongjiang Province, with 336 employees, including 21 in R&D, and 149 in sales and marketing. The products of Nutrastar are sold throughout China via a sales and distribution network that covers more than 10 provinces. More information may be found at http://www.nutrastarintl.com/ or e-mail: ir@nutrastarintl.com

Make sure you are first to receive timely up-to-date information on Nutrastar. Sign up for Nutrastar’s email news alert system today at: http://www.nutrastarintl.com/alerts

Safe Harbor Statement

This news release contains “forward-looking statements” relating to the business of Nutrastar International Inc., its subsidiaries and other affiliate companies. All statements, other than statements of historical fact included herein are “forward-looking statements” including statements concerning plans, objectives, goals, strategies, future events or performance, and underlying assumptions and other statements that are other than statements of historical facts. These forward-looking statements are often identified by the use of forward-looking terminology such as “believes,” “expects” or similar expressions. These statements are subject to uncertainties and risks including, but not limited to, product and service demand and acceptance, changes in technology, economic conditions, the impact of competition and pricing, government regulation, and other risks contained in reports filed by the Company with the Securities and Exchange Commission. All forward-looking statements attributable to the Company or persons acting on its behalf are expressly qualified in their entirety by these factors. You should not place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Other than as required under the securities laws, the Company does not assume a duty to update any forward-looking statements to reflect events or circumstances after the date hereof.

For more information, please contact:

Richard Hull
American Capital Ventures
Tel: +1-305-918-7000
Email: rh@amcapventures.com

NUTRASTAR INTERNATIONAL INC. AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF INCOME AND COMPREHENSIVE INCOME

(AMOUNTS EXPRESSED IN US DOLLARS)

Year Ended December 31,

2014

2013

REVENUE

$

43,328,218

$

43,348,989

Cost of goods sold

(9,315,526)

(9,633,349)

GROSS PROFIT

34,012,692

33,715,640

Selling expenses

(1,467,320)

(1,848,488)

General and administrative expenses

(2,376,873)

(3,216,459)

Gain on re-measurement of accrued staff fringe and social benefits

934,855

Income from operations

30,168,499

29,585,548

Other income (expenses):

Interest income

399,696

324,145

Foreign exchange differences

(10,765)

64,653

Change in fair value of warrants

173

Other income

32,558

8,073

Total other income (expenses)

421,489

397,044

Income before income taxes

30,589,988

29,982,592

Provision for income taxes

(7,870,214)

(7,812,222)

NET INCOME

22,719,774

22,170,370

OTHER COMPREHENSIVE INCOME:

Foreign currency translation adjustments

(324,662)

3,109,485

COMPREHENSIVE INCOME

$

22,395,112

$

25,279,855

Earnings per share

Basic

$

1.34

$

1.38

Diluted

$

1.28

$

1.30

Weighted average number of shares outstanding

Basic

16,827,010

15,949,537

Diluted

17,699,589

17,089,460

NUTRASTAR INTERNATIONAL INC. AND SUBSIDIARIES

CONSOLIDATED BALANCE SHEETS

(AMOUNTS EXPRESSED IN US DOLLARS)

December 31,

2014

2013

ASSETS

CURRENT ASSETS

Cash and cash equivalents

$

126,542,564

$

102,599,186

Accounts receivable

93,066

56,922

Inventories

635,409

691,847

Prepayments and other receivables

1,489,800

1,300,012

Total current assets

128,760,839

104,647,967

OTHER ASSETS

Intangible assets, net

613,315

1,107,737

Property, plant and equipment, net

14,424,942

15,481,249

Total assets

$

143,799,096

$

121,236,953

LIABILITIES AND STOCKHOLDERS’ EQUITY

CURRENT LIABILITIES

Other payables and accruals

$

990,290

$

1,167,957

Taxes payable

2,748,583

2,879,172

Due to a related party

511,054

265,223

Preferred stock dividend payable

690,662

738,903

Total current liabilities

4,940,589

5,051,255

Total liabilities

4,940,589

5,051,255

COMMITMENTS AND CONTINGENCIES

STOCKHOLDERS’ EQUITY

Preferred Stock, $0.001 par value, 1,000,000 shares authorized, 77,776
shares and 110,066 shares issued and outstanding, respectively;
aggregate liquidation preference amount: $2,177,728 and $3,081,848,
plus accrued but unpaid dividend of $690,662 and $738,903, at
December 31, 2014 and 2013, respectively

1,773,772

2,510,183

Common stock, $0.001 par value, 190,000,000 shares authorized,
16,953,541 shares issued and 16,909,986 shares outstanding at
December 31, 2014; 16,421,161 shares issued and 16,377,606 shares
outstanding at December 31, 2013

16,954

16,422

Additional paid-in capital

21,122,372

19,934,551

Statutory reserves

4,989,033

4,983,935

Treasury stock, at cost, 43,555 shares as of December 31, 2014 and 2013

(78,767)

(78,767)

Retained earnings

102,783,308

80,242,877

Accumulated other comprehensive income

8,251,835

8,576,497

Total stockholders’ equity

138,858,507

116,185,698

Total liabilities and stockholders’ equity

$

143,799,096

$

121,236,953

NUTRASTAR INTERNATIONAL INC. AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF CASH FLOWS

(AMOUNTS EXPRESSED IN US DOLLARS)

Year Ended December 31,

2014

2013

CASH FLOWS FROM OPERATING ACTIVITIES:

Net income

$

22,719,774

$

22,170,370

Adjustments to reconcile net income to cash provided by operating activities:

Change in fair value of warrants

(173)

Depreciation and amortization

1,485,039

1,473,496

Share-based compensation expense

137,085

801,396

IR unregistered stock compensation expense

92,371

17,804

(Increase) decrease in assets:

Accounts receivable

(36,209)

26,676

Inventories

53,730

298,548

Prepayments and other receivables

(193,731)

61,626

Increase (decrease) in liabilities:

Other payables and accruals

(173,184)

Advance from related party

237,956

(351,591)

Taxes payable

(119,724)

(191,162)

Net cash provided by operating activities

24,203,107

24,306,990

CASH FLOWS FROM FINANCING ACTIVITIES:

Advance from related party

16,637

46,173

Net cash provided by financing activities

16,637

46,173

Foreign currency translation adjustment

(276,366)

2,719,490

INCREASE IN CASH AND CASH EQUIVALENTS

23,943,378

27,072,653

CASH AND CASH EQUIVALENTS, at the beginning of the period

102,599,186

75,526,533

CASH AND CASH EQUIVALENTS, at the end of the period

$

126,542,564

$

102,599,186

NON-CASH TRANSACTIONS

Preferred stock and dividend converted into common stock

$

958,897

$

86,279

Preferred stock dividend payable

174,245

229,513

Share-based payment to officers and directors under equity incentive plan

137,085

801,396

Share-based payment — IR unregistered stock compensation expense

92,371

17,804

SUPPLEMENTAL DISCLOSURE INFORMATION

Income taxes paid

$

7,970,444

$

7,683,689

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/nutrastar-international-inc-announces-full-year-2014-results-300057454.html

Sigma-Aldrich Announces Exclusive Distribution Agreement with Roche

– Provides Researchers with Global Access to Roche Biochemical Reagents Product Portfolio

ST. LOUIS, March 19, 2015 /PRNewswire/ — Sigma-Aldrich Corporation (NASDAQ: SIAL), a leading Life Science and Technology company, announced today it signed an exclusive global distribution agreement with Roche (SIX: RO, ROG; OTCQX: RHHBY). The agreement pairs Roche’s high-quality Biochemical Reagents product portfolio with the industry-leading eCommerce and supply chain capabilities of Sigma-Aldrich.

Under the agreement, Sigma-Aldrich will employ its sales, marketing and eCommerce expertise, and leverage the strength of its relationships with the scientific community, to present and distribute the Roche Biochemical Reagents product portfolio, which includes kits and enzymes for cellular analysis, proteomics and conventional PCR applications. For more information, visit www.sigma-aldrich.com/roche.

“Sigma-Aldrich is excited to offer the global scientific community access to Roche’s leading portfolio of scientific tools and reagents. The addition of these life science tools supports our strategy to augment our portfolio with products that accelerate customer scientific research programs,” said Eric Green, Executive Vice President and President, Sigma-Aldrich Research. “We look forward to working with Roche in this relationship.”

“This agreement allows us to provide more customers with access to high-quality Roche Biochemical Reagent products through Sigma-Aldrich’s expanded eCommerce and distribution networks,” said Paul Brown, Head of Roche Molecular Diagnostics. “In addition, this will provide us the flexibility to devote more resources to our primary focus areas.”

Transition of the Roche portfolio to Sigma-Aldrich is expected to take place in 2015. In the interim, these products will continue to be available through existing Roche channels. For more information, visit the Roche or Sigma-Aldrich websites.

©2015 Sigma-Aldrich Co. LLC. All rights reserved. Sigma-Aldrich and SAFC are trademarks of Sigma-Aldrich Co. LLC or its affiliates, registered in the U.S. and other countries.

Sigma-Aldrich and Sigma are trademarks of Sigma-Aldrich Co. LLC., registered in the US and other countries.

GenSpera Presents at BIO Asia International Conference

— Company CEO to Showcase the Potential of Its Science

SAN ANTONIO, March 17, 2015 /PRNewswire/ — GenSpera Inc. (OTCQB: GNSZ) announced today that Craig Dionne, Ph.D., chief executive officer at GenSpera, will present at the 12th Annual BIO Asia International Conference on Tuesday, March 24 at 3:15 p.m. JST at the Grand Hyatt in Tokyo, Japan. The presentation will offer an overview of the latest scientific developments of GenSpera’s lead investigational agent mipsagargin and the applicability of its innovative mechanism of action in a broad array of oncology treatments.

The 12th Annual BIO Asia International Conference, co-hosted by the Biotechnology Industry Organization (BIO), BioCentury and the Japan Bioindustry Association (JBA), brings together the global biotechnology and pharmaceutical industry to explore licensing and research collaborations in the current Asia-Pacific business and policy environments. GenSpera is exploring partnership opportunities in Asia to assist in further development of mipsagargin as a treatment for hepatocellular carcinoma (HCC).

“This conference is a key opportunity for GenSpera to build on its partner connections in one of our primary markets and evaluate multiple business opportunities to continue our positive progress with mipsagargin,” said Dionne. “Our approach of working on global business fronts while continuing systematic and scientifically sound clinical development will help bring new treatment options to patients quickly and efficiently.”

GenSpera’s approach to development for mipsagargin sets it apart among agents currently being studied for the treatment of HCC, the most common cancer diagnosis in Southeast Asia. GenSpera’s BIO Asia presentation follows the company’s presentation of positive Phase II study results for mipsagargin in treating HCC at the 2015 Gastrointestinal Cancers Symposium in San Francisco, Calif. About half of the liver cancer cases in the world occur in China where more than 350,000 people per year die from HCC. Globally, rates of HCC are on the rise, making it one of the ten most common cancers with more than 750,000 diagnosed each year.

“Our Phase II study validated proof of concept for our platform technology and cleared the way for GenSpera to continue our work,” continued Dionne. “With our patents on the platform in place, we are well positioned to build on our approach of strategic partnerships and expand our work in Asia which has high demand for new targeted HCC treatments.”

Mipsagargin’s mechanism of action works by targeting the enzyme prostate-specific membrane antigen (PSMA), which is highly expressed in cancer tumor vasculature and in prostate cancer cells. The Phase II study results presented in San Francisco demonstrated that the prodrug effectively stabilizes progression of HCC by reducing blood flow within tumors while not affecting blood flow within normal tissues. The study also showed indications that patients had improved quality of life and fewer side effects than typically seen in cancer treatment. GenSpera is undertaking multiple trials in different indications in order to show that mipsagargin is effective across a broad array of cancer tumor types.

About GenSpera
GenSpera Inc. is a San Antonio-based biotech company that unlocks conventional thinking to conceive, design, and develop cancer therapies. GenSpera’s technology platform combines a powerful, plant-derived cytotoxin (thapsigargin) with a patented prodrug delivery system that provides for targeted release of drug candidates within tumors. GenSpera’s lead drug candidate, mipsagargin, was granted Orphan Drug designation by the U.S. Food and Drug Administration (FDA) in 2013 for evaluation in patients with hepatocellular carcinoma (liver cancer).

For additional information on GenSpera, visit www.genspera.com and connect on Twitter, LinkedIn, Facebook, YouTube and Google+.

Cautionary Statement Regarding Forward Looking Information
This communication may contain forward-looking statements. Investors are cautioned that statements in this document regarding potential applications of GenSpera’s technologies or the future prospects of the company constitute forward-looking statements that involve risks and uncertainties, including, without limitation, risks inherent in the development and commercialization of potential products, uncertainty of clinical trial results or regulatory approvals or clearances, need for future capital, dependence upon collaborators and maintenance of our intellectual property rights and the acceptance of GenSpera’s proposed therapies by the health community. Actual results may differ materially from the results anticipated in these forward-looking statements. Additional information on potential factors that could affect our results and other risks and uncertainties will be detailed from time to time in GenSpera’s periodic reports filed with the Securities and Exchange Commission.

Sky News, Helen Dalley interviews Dr Graham Kelly

SYDNEY, March 10, 2015 /PRNewswire/ — Novogen Ltd (ASX: ‘NRT’; Nasdaq: ‘NVGN’) CEO, Dr Graham Kelly, PhD, was interviewed by Sky News, Helen Dalley about the breakthrough brain cancer drug being developed by Novogen. Novogen is an Australian-US drug discovery company focused on the clinical development of drugs targeting two novel drug targets pertinent to a range of therapeutic indications.

The interview can be viewed at http://goo.gl/PH737R.

About Novogen Limited

Novogen is a public, drug-development company whose shares trade on both the Australian Securities Exchange (‘NRT’) and NASDAQ (‘NVGN’).  The Novogen Group includes a New Haven CT – based joint venture company, CanTx Inc., with Yale University.

Novogen has two Novogen has two main drug technology platforms: super-benzopyrans (SBPs) and anti-tropomyosins (ATMs). SBP compounds have been created to kill the full range of cells within a tumor, but particularly the cancer stem cells. The ATM compounds target the microfilament component of the cancer cell and when used in conjunction with standard anti-microtubular drugs, result in comprehensive and fatal destruction of the cancer cell’s cytoskeleton. Ovarian cancer, colorectal cancer, malignant ascites, prostate cancer, neural cancers (glioblastoma, neuroblastoma in children) and melanoma are the key clinical indications being pursued, with the ultimate objective of employing both technologies as a unified approach to first-line therapy.

Further information is available on our website: www.novogen.com

For more information please contact:

Corporate Contact

Dr. Graham Kelly

Executive Chairman & CEO

Novogen Group

Graham.Kelly@novogen.com           

+61 (0) 2 9472 4100

Media Enquiries

Cristyn Humphreys

Chief Operating Officer

Novogen Group

Cristyn.Humphreys@novogen.com

+61 (0) 2 9472 4111

eBullion Inc. Wholly Owned Subsidiary Man Loong Bullion Earned Top 10 Most Active Loco London Gold/Silver Dealer Award 2013/14 In Hong Kong

NEW YORK, January 20, 2015 /PRNewswire/ — eBullion Inc. (EBML) wholly owned subsidiary Man Loong Bullion earned a Top 10 Most Active Loco London Gold/Silver Dealer Award 2013/14 in Hong Kong.

At year end, the Chinese Gold and Silver Exchange Society (“CGSE”) in Hong Kong reviews all its members’ trading volume of Loco London Gold/Silver in the past year and gives awards to the top 10 most active members in the trading of Loco London Gold/Silver. eBullion Inc. wholly owned subsidiary Man Loong Bullion Company Limited is proud to receive the Top 10 Most Active Loco London Gold/Silver Dealer Award 2014.

Reference: http://cgse.com.hk/upload/ebook/original/688695849804.Final%20Version.pdf

Man Loong Bullion is an officially designated electronic trading member of the Chinese Gold and Silver Exchange Society (“CGSE”), a self-regulatory organization registered in Hong Kong which acts as an exchange for the trading of gold and silver. Man Loong holds a Type AA License with the CGSE, which authorizes it to engage in the electronic trading of Kilo Gold and Loco London Gold and Silver on behalf of its clients.

The CGSE’s constitution limits CGSE membership to 192 members, all of whom must have a minimum required working capital, defined as cash plus precious metals, of approximately $193,000 and minimum required assets of $643,000. The CGSE requires its members to submit a quarterly liquidity capital report, in order to ensure that the bank balances exceed or equal the balance of customer deposits. Man Loong was in compliance with these requirements.

Though its wholly owned subsidiary Man Loong Bullion, eBullion Inc, (EBML) is able to access the Gold and Silver trading markets in China by business resources provided by the Chinese Gold and Silver Exchange Society (“CGSE”).

To learn more about eBullion Inc, visit the company website at http://www.ebulliongroup.com/. Telephone: (+852) 2155-3999 E-mail: online@manloong.com

Disclaimer

This press release contains forward-looking statements that may involve risks and uncertainties. The statements contained in this press release that are not purely historical are forward-looking statements within the meaning of Section 27A of the Securities Act and Section 21E of the Exchange Act. When used in this press release, the words “plan”, “target”, “anticipate,” “believe,” “estimate,” “intend” and “expect” and similar expressions are intended to identify such forward-looking statements. Such forward-looking statements include, without limitation, the statements regarding eBullion’s strategy, future plans for business development, future expenses and costs, future liquidity and capital resources, and estimates of business profit. All forward-looking statements in this press release are based upon information available to eBullion on the date of the release, and eBullion assumes no obligation to update any such forward-looking statements. Forward looking statements involve a number of risks and uncertainties, and there can be no assurance that such statements will prove to be accurate. The company’s actual results could differ materially from those discussed in this press release. In particular, there can be no assurance that business development will continue at any specific progress. Factors that could cause or contribute to such differences include, but are not limited to, those discussed in the company’s 10-K filed with the U.S. Securities Exchange Commission.

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/ebullion-inc-wholly-owned-subsidiary-man-loong-bullion-earned-top-10-most-active-loco-london-goldsilver-dealer-award-201314-in-hong-kong-300022693.html

China Jo-Jo Drugstores Added Eight Retail Pharmacies to Bring the Total Store Count to Over 60

HANGZHOU, China, January 15, 2015 /PRNewswire/ — China Jo-Jo Drugstores, Inc. (NASDAQ CM: CJJD) (the “Company” or “China Jo-Jo“), a leading China-based retail and wholesale distributor of pharmaceutical and health care products through its own online and retail pharmacies, announced today that it opened eight new retail pharmacies in Hangzhou on January 10, 2015, a company record for same-day store openings. The Company now owns and operates a total of 61 retail drugstores in China.

The eight added drugstores are among the eleven pharmacies which the Company acquired from Hangzhou Sanhao Grand Pharmacy Chain Co., Ltd. on October 9, 2014. These pharmacies had been remodeled with significant improvement and relocated to better locations, more in line with the Company’s business model of carrying thousands of pharmaceutical and healthcare products in each store, and offering better in-store experience to our customers. The new stores have been re-located to be much closer to several major residential areas, thus greatly enhancing the Company’s store penetration in Hangzhou. China Jo-Jo’s existing network of 61 pharmacies will also serve as potential delivery platforms when the Company unveils its Online-to-Offline (O2O) strategy in 2015.

Four of the new pharmacies are currently qualified to take Social Health Insurance (“SHI”), China’s national health insurance plan aimed to provide universal health insurance coverage to Chinese citizens. The other four pharmacies have passed all SHI tests and are expected to be qualified within two or three months.Traditionally, SHI participants, who tend to be our long term customers, account for more than 50% of the Company’s retail pharmacy sales.

Mr. Lei Liu, Chairman and CEO of the Company stated, “We are delighted to see the strong launch of our new pharmacies to kick off the New Year. In anticipation of Chinese government’s approval for online prescription drug sales in 2015, we are making various strategic moves by focusing on product offerings, and easy accessibility of our online and offline stores.”

About China Jo-Jo Drugstores, Inc.

China Jo-Jo Drugstores, Inc., through its own retail drugstores, wholesale distributor and online pharmacy, is a leading retailer and wholesale distributor of pharmaceutical and healthcare products in China. As of September 30, 2014, the Company had 51 retail pharmacies in Hangzhou. The Company’s wholesale subsidiary not only supplies its retail stores, but also distributes drug and other healthcare products to other drugstores and drug vendors. The Company routinely posts important information on its corporate websites at www.jiuzhou-drugstore.com (Chinese) and www.chinajojodrugstores.com (English).

Forward Looking Statement

Statements in this press release regarding the Company that are not historical facts are forward-looking statements and are subject to risks and uncertainties that could cause actual future events or results to differ materially from such statements. Any such forward-looking statements, including, but not limited to, financial guidance, are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements can be identified by the use of forward-looking terminology such as “believe,” “expect,” “may,” “will,” “should,” “project,” “plan,” “seek,” “intend,” “anticipate,” the negatives thereof, or comparable terminology. Such statements typically involve risks and uncertainties and may include financial projections or information regarding the progress of new product development. It is routine for the Company’s internal projections and expectations to change as the quarter and year progresses, and therefore it should be clearly understood that the internal projections and beliefs upon which the Company bases its expectations may change. Although these expectations may change, the Company is under no obligation to inform you if they do. Actual results could differ materially from the expectations reflected in such forward-looking statements as a result of numerous factors, including the risks associated with the effect of changing economic conditions in the People’s Republic of China, variations in cash flow, reliance on collaborative retail partners and on new product development, variations in new product development, risks associated with rapid technological change, and the potential of introduced or undetected flaws and defects in products. Readers are referred to the reports and documents filed from time to time by the Company with the Securities and Exchange Commission for a discussion of these and other important risk factors that could cause actual results to differ from those discussed in forward-looking statements.

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/china-jo-jo-drugstores-added-eight-retail-pharmacies-to-bring-the-total-store-count-to-over-60-300021160.html

China Jo-Jo Drugstores Signed Strategic Service Agreement with Alipay to Provide Online Payment Service to its Customers

HANGZHOU, China, January 8, 2015 /PRNewswire/ — China Jo-Jo Drugstores, Inc. (NASDAQ CM: CJJD) (the “Company” or “China Jo-Jo“), a leading China-based retail and wholesale distributor of pharmaceutical and health care products through its own online and retail pharmacies, announced that it has recently signed a service agreement with Alipay (China) Internet Technology Ltd. (“Alipay”) to launch an online payment service (“Alipay Service”) for its customers. With over 300 million registered users and over 200 partnering financial institutions, Alipay is China’s dominant third-party online payment provider which processes about 50% of China’s e-commerce transactions, including mobile payments.

Through Alipay’ s popular services such as Alipay and Alipay Wallet, Chinese consumers can now make e-payment for China Jo-Jo’s products, in both retail and online pharmacies, through mobile devices such as smartphones. China Jo-Jo will be able to better engage mobile consumers through such features in the Alipay Service Window as push notifications for deals and sales promotions, app download and customer service. In addition, Alipay’s enterprise software offers the Company better management tools, including transaction management, big data collection, marketing and financial control.

Mr. Lei Liu, Chairman and CEO of China Jo-Jo, stated, “Our cooperation with Alipay gives us a great opportunity to get access to Alipay’s 300 million registered users who, like most Chinese consumers, are seeking more convenient pharmacy shopping experiences. In addition to maintaining our traditional customer base, we hope to attract more young, affluent, and tech-savvy consumers by answering to their needs for pharmaceutical and healthcare products.”

About China Jo-Jo Drugstores, Inc.

China Jo-Jo Drugstores, Inc., through its own retail drugstores, wholesale distributor and online pharmacy, is a leading retailer and wholesale distributor of pharmaceutical and healthcare products in China. As of September 30, 2014, the Company had 51 retail pharmacies in Hangzhou. The Company’s wholesale subsidiary not only supplies its retail stores, but also distributes drug and other healthcare products to other drugstores and drug vendors. The Company routinely posts important information on its corporate websites at www.jiuzhou-drugstore.com (Chinese) and www.chinajojodrugstores.com (English).

About Alipay (China) Internet Technology Ltd.

Launched in 2004, Alipay (www.alipay.com) is a commonly used third-party online payment solution in China. Alipay provides an escrow payment service that reduces transaction risks for online consumers. As of the end of 2013, the number of Alipay registered users reached 300 million and the number of partnering financial institutions exceeded 200. In addition, Alipay handles over 80 million transactions daily, 45 million of which are through mobile payment accounts. In November 2013, Alipay’s mobile application, Alipay Wallet, started operating as an independent brand. As of today, there are 190 million annual active users. In addition to providing basic services such as shopping payment, credit card repayment, money transfer, and utilities bill payment on mobile phones, Alipay Wallet is expanding its offline applications to shopping malls, convenience stores, taxis and hospitals. Alipay partners with multiple financial institutions including leading national and regional banks across China as well as Visa and MasterCard to facilitate payments in China and abroad. Apart from Taobao Marketplace and Tmall.com, Alipay provides payment solutions to merchants in a wide range of industries including online retail, virtual gaming, digital communications, commercial services, air ticketing and utilities. It also offers an online payment solution to help merchants worldwide sell directly to consumers in China and supports transactions in 14 major foreign currencies.

Alipay (China) Internet Technology Ltd. is an affiliate of Alibaba Group Holdings, Ltd. (NYSE: BABA).

Forward Looking Statement

Statements in this press release regarding the Company that are not historical facts are forward-looking statements and are subject to risks and uncertainties that could cause actual future events or results to differ materially from such statements. Any such forward-looking statements, including, but not limited to, financial guidance, are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements can be identified by the use of forward-looking terminology such as “believe,” “expect,” “may,” “will,” “should,” “project,” “plan,” “seek,” “intend,” “anticipate,” the negatives thereof, or comparable terminology. Such statements typically involve risks and uncertainties and may include financial projections or information regarding the progress of new product development. It is routine for the Company’s internal projections and expectations to change as the quarter and year progresses, and therefore it should be clearly understood that the internal projections and beliefs upon which the Company bases its expectations may change. Although these expectations may change, the Company is under no obligation to inform you if they do. Actual results could differ materially from the expectations reflected in such forward-looking statements as a result of numerous factors, including the risks associated with the effect of changing economic conditions in the People’s Republic of China, variations in cash flow, reliance on collaborative retail partners and on new product development, variations in new product development, risks associated with rapid technological change, and the potential of introduced or undetected flaws and defects in products. Readers are referred to the reports and documents filed from time to time by the Company with the Securities and Exchange Commission for a discussion of these and other important risk factors that could cause actual results to differ from those discussed in forward-looking statements.

Contacts

China Jo-Jo Drugstores, Inc.
Ming Zhao
Chief Financial Officer
Tel: (561) 372-5555
Email: frank.zhao@jojodrugstores.com

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/china-jo-jo-drugstores-signed-strategic-service-agreement-with-alipay-to-provide-online-payment-service-to-its-customers-300017804.html

Biostar Pharmaceuticals, Inc. Announces Signing of Joint Research and Development Agreement with Northwest University for Further Development of Danshensu Yibingzhi (IDHP), a Class One Drug for Treatment of Cardiovascular Diseases

XIANYANG, China, January 8, 2015 /PRNewswire/ — Biostar Pharmaceuticals, Inc. (NASDAQ: BSPM) (“Biostar” or “the Company”), a PRC-based manufacturer and marketer of pharmaceutical and health supplement products in China for a variety of diseases and conditions, today announced that on December 29, 2014, the Company signed a joint research and development agreement with Northwest University, one of China’s leading comprehensive universities located in Xi’an city, Shaanxi Province, for further development of Danshensu Yibingzhi (IDHP), a Class One drug for treatment of cardiovascular diseases to further research and development efforts in connection with Danshensu Yibingzhi (IDHP).

Danshensu Yibingzhi (IDHP) was developed by Professor Xiaohui Zheng and his research team after 14 years of concerted research effort and was recently approved by the Education Department of Shaanxi Province and The Finance Department of Shaanxi Province for the further industrialization and marketization. Professor Zheng is the Company’s Chief Scientist and is affiliated with Northwest University. There are currently two invention patents associated with Danshensu Yibingzhi (IDHP) (patent Nos. ZL200410026105.3 and ZL201010577073.9) both of which are held by Northwest University. Professor Zheng leads a large joint team that includes nearly 100 researchers from over twenty different organizations, including the University of Cambridge, King’s College of London University, Peking University, Chinese Military Medical Science Academy of the PLA, the Fourth Military Medical University and Shaanxi People’s Hospital, among others. The Company believes that Northwest University chose to cooperate and collaborate with the Company research team for further research and development of Danshensu Yibingzhi (IDHP) in light of the Company’s own research and development track record with Danshen Granules, Zushima Analgesic Spray, Zhitong Tougu Plaster, Qianlietong, Hyperthyroidism Capsules, among others.

According to the statistics, there are more than 280 million Chinese patients (or approximately 20% of China’s total population) are suffering from cardiovascular diseases. In light of this, the Chinese government set the prevention and treatment of cardiovascular and other diseases as a major development strategy since its most recently adopted “Eleventh Five-Year Plan.” In particular, the governmental effort is directed to support development of innovative treatments and technologies and to challenge PRC’s medical research and scientific communities to advance the field of available treatment options.

Mr. Ronghua Wang, Chairman and CEO of Biostar, commented on this development: “The PRC government set the prevention and treatment of cardiovascular and other related diseases as a national development strategy in its “Eleventh Five-Year Plan.” In recent years, we have focused our efforts on researching and developing new drugs to treat cardiovascular and related diseases. We view our ongoing cooperation with Northwest University as a major step in this effort. We expect to continue our combined efforts on this project in the next five years. In that time period, we anticipate that various organizations/institutions and numerous experts in the field will join and/or participate in this research effort. The Company believes that our ongoing cooperation with Northwest University on this project will provide a solid foundation for the Company’s efforts and development in this area in the years to come,” Mr. Wang concluded.

About Biostar Pharmaceuticals, Inc.

Biostar Pharmaceuticals, Inc., through its wholly owned subsidiary and controlled affiliate in China, develops, manufactures and markets pharmaceutical and health supplement products for a variety of diseases and conditions. The Company’s most popular product is its Xin Aoxing Oleanolic Acid Capsule, an over-the-counter (“OTC”) medicine for chronic hepatitis B, a disease affecting approximately 10% of the Chinese population. For more information please visit: http://www.biostarpharmaceuticals.com.

Safe Harbor Relating to the Forward-Looking Statements

Certain statements in this release concerning our future growth prospects are forward-looking statements, within the meaning of Section 27A of the U.S. Securities Act of 1933, as amended, and Section 21E of the U.S. Securities Exchange Act of 1934, as amended, which involve a number of risks and uncertainties that could cause actual results to differ materially from those in such forward-looking statements. The Company uses words and phrases such as “guidance,” “forecasted,” “projects,” “is expected,” “remain confident,” “will” and similar expressions to identify forward-looking statements in this press release, including forward-looking statements. Undue reliance should not be placed on forward-looking information. Forward-looking information is based on current expectations, estimates and projections that involve a number of risks, which could cause actual results to vary and in some instances to differ materially from those anticipated by Biostar and described in the forward-looking information contained in this news release. The risks and uncertainties relating to these statements include, but are not limited to, risks and uncertainties regarding the Company’s ability to successfully commercialize the new drug subject of this press release, its ability to expand and maintain its research and development efforts, its ability to sustain its sales effort going forward, its ability to retain existing and retain new customers for its products, its ability to achieve the projected sales through the efforts of the call center, to complete the contemplated clinical trials and capitalize on such opportunities, the state of consumer confidence and market demand or the Company’s products, success of its investments, risks and uncertainties regarding fluctuations in earnings, our ability to sustain our previous levels of profitability, including on account of our ability to manage growth, intense competition, wage increases in China, its ability to attract and retain highly skilled professionals, time and cost overruns on fixed-price, fixed-time frame contracts, client concentration, its ability to successfully complete and integrate potential acquisitions, withdrawal of governmental fiscal incentives, political instability and regional conflicts and legal restrictions on raising capital or acquiring companies outside China. Additional risks that could affect our future operating results are more fully described in our United States Securities and Exchange Commission filings including our most recent Annual Report on Form 10-K for the year ended December 31, 2013, and other subsequent public filings. These filings are available at www.sec.gov. We may, from time to time, make additional written and oral forward-looking statements, including statements contained in our filings with the Securities and Exchange Commission and our reports to shareholders. We do not undertake to update any forward-looking statements that may be made from time to time by or on our behalf.

For more information contact:

Biostar Pharmaceuticals, Inc.
Ally Gong
Tel: +86-29-3368-6638
Email: office@aoxing-group.com

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/biostar-pharmaceuticals-inc-announces-signing-of-joint-research-and-development-agreement-with-northwest-university-for-further-development-of-danshensu-yibingzhi-idhp-a-class-one-drug-for-treatment-of-cardiovascular-diseases-300017713.html